How to dose a psychotropic drug: Beyond therapeutic drug monitoring to genotyping the patient

Acta Psychiatrica Scandinavica

Volumn 122, Issue 6, 2010, Pages 440-441

  Stahl, Stephen M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT;

CLINICAL PRACTICE; DRUG ABSORPTION; DRUG EFFICACY; DRUG INFORMATION; DRUG METABOLISM; DRUG MONITORING; GENOTYPE; HUMAN; NOTE; PATIENT COMPLIANCE; PHENOTYPE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY;

ANTIPSYCHOTIC AGENTS; CLOPENTHIXOL; DRUG MONITORING; GENOTYPE; HUMANS; PSYCHOTROPIC DRUGS;

EID: 78149387778     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2010.01606.x     Document Type: Note

References (8)

1. Davies S, Westin A, Castberg I et al. Characterization of zuclopenthixol metabolism by in vitro and therapeutic drug monitoring studies. Acta Psychiatr Scand 2010;122:444-453.
2. Stahl SM. Stahls essential psychopharmacology prescribers guide: zuclopenthixol, 3rd edn. New York: Cambridge University Press, 2009:613-617.
3. Stahl SM. Stahls essential psychopharmacology prescribers guide, 3rd edn. New York: Cambridge University Press, 2009.
4. Citrome L, Jaffe A, Levine J. Dosing of second generation antipsychotic medication in a state hospital system. J Clin Psychopharmacol 2005;25:388-390.
5. Cutler A, Ball S, Stahl SM. Dosing atypical antipsychotics. CNS Spectr 2008;9:1-16.
6. Schwartz T, Stahl SM. Treatment strategies for dosing the second generation antipsychotics. CNS Neurosci Ther. In press.
7. Mrazek DA. Psychiatric pharmacogenomics. New York: Oxford University Press, 2010.
8. Stahl SM. Personalized medicine, pharmacogenomics, and the practice of psychiatry: on the threshold of predictive therapeutics in psychopharmacology? CNS Spectr 2008;13:115-118.